A pivotal study of bb-2121 in patients with relapsed/refractory multiple myeloma

Trial Profile

A pivotal study of bb-2121 in patients with relapsed/refractory multiple myeloma

Planning
Phase of Trial: Phase III

Latest Information Update: 04 May 2017

At a glance

  • Drugs Bb 2121 (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 04 May 2017 New trial record
    • 27 Apr 2017 According to a Celgene Corporation media release, Celgene and bluebird bio plan to initiate this trial by year-end.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top